1
A study reveals a possible explanation for why checkpoint blockade inhibitors don’t work well for some patients whose tumors have a high mutational burden.
A study reveals a possible explanation for why checkpoint blockade inhibitors don’t work well for some patients whose tumors have a high mutational burden.